MNOV: Multiple Abstracts Presented at 92nd EAS Congress
On May 28, 2024, MediciNova, Inc. (MNOV) announced that two abstracts regarding MN-001 (tipelukast) and MN-002 were presented as posters at the...
U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?
Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the...
Investment Thesis and Valuation
Key Drivers MN-166 (ibudilast, PhIIb) and MN-001 (tipelukast, PhII) together targeting potential market worth $3-4b. Positive MN-166 (ibudilast) Ph...
No more insights